Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · opportunities

Moderna's mRNA flu vaccine approved by FDA. When is it available?

23 August 2026 · By · Wire by Fusion42

Published

23 August 2026

Topic

opportunities

◆ Sectors

Health

◆ Geography

United States

◆ Source

Read at medicalnewstoday.com →

◆ Verified

Fusion42 · 23 August 2026 · Fusion42 review

The FDA has approved Moderna's mRNA flu vaccine mFLUSIVA for adults aged 50 and older, offering a faster production method that could better match changing flu strains. The vaccine showed superior effectiveness to standard flu shots in clinical trials and may be available for the 2026-2027 flu season in the US.

This Wire brief sits within Fusion42's coverage of Health, and 12 sources have reported it between 6 Aug 2026 and 27 Aug 2026.

◆ ◆ The Wire takeaway

You face a new market opening with the first mRNA flu vaccine approved for over-50s. Expect demand shifts as this vaccine challenges traditional egg-based flu shots in speed and effectiveness.

◆ Coverage

12 sources · first reported 6 Aug 2026 · latest 27 Aug 2026

◆ Related on Wire

◆ Topics

HealthmRNAflu-vaccineFDA-approvalclinical-trialinfectious-disease